PDS Biotechnology Corp
PDS0101
HPV16-positive recurrent and/or metastatic Head and Neck Cancer
Date
TBD
Phase 2 readout · Date TBD estimated
What's at stake
Phase 2 trial results for PDS0101 in HPV16-positive recurrent and/or metastatic Head and Neck Cancer are due Date TBD. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 15h ago
“The amendment is supported by positive final results from the Company’s VERSATILE-002 trial, which showed promising mOS and durable PFS.”